Login
$CRDF
$0.91 +$0.18 (24.97%) Live

$CRDF SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
12 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms

12 Nov 2026 10-Q
27 Oct 2026 Form 3: Alland Leila, Chief Medical Officer

No securities owned

27 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Seasoned oncology executive brings extensive clinical development expertise and a track record of advancing innovative cancer therapies

22 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

On October 22, 2026, Cardiff Oncology, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). A total of 48,084,246 shares of common stock, constituting a quorum, were represented in person or by valid pro...

14 Sep 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

26 Aug 2026 DEFA14A
26 Aug 2026 DEF 14A
14 Aug 2026 PRE 14A
11 Aug 2026 8-K: Results of Operations and Financial Condition

Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC

11 Aug 2026 10-Q
27 Jul 2026 SCHEDULE 13G/A
21 Jul 2026 S-8
16 Jul 2026 Form 4: Pace Gary W, Director

Bought 687,285 shares ($1M) · Acquired 687,285 Common Stock Purchase Warrant (Open Market Purchase)

16 Jul 2026 Form 4: Mohindru Mani, Director

Bought 34,364 shares ($50K) · Acquired 34,364 Common Stock Purchase Warrant (Open Market Purchase)

16 Jul 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2026, between Cardiff Oncology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its ...

16 Jul 2026 424B5
22 Jun 2026 Form 4: Mohindru Mani, Director

Bought 24,703 shares ($29.9K)

22 Jun 2026 Form 4: Pace Gary W, Director

Bought 30,000 shares ($36.6K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support